GlassScriptPhysician profile
Yousef Hasan
NPI 1194330761
$4,375.28
in general payments reported to CMS, 2019-2025
32 companies · $3,371 in 2025
The $3,371 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,004 · 2025: $3,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554 · Education: $522 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.27 |
| Education | $521.91 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $693.58 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Novartis Pharmaceuticals Corporation | $506.54 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $454.53 | 2024-2025 | Lynparza, Calquence, Imfinzi |
| Daiichi Sankyo INC. | $377.83 | 2024-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $312.81 | 2024-2025 | Soliris, Ultomiris |
| Incyte Corporation | $279.80 | 2025 | Zynyz, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $220.10 | 2025 | Rybrevant, Carvykti, Talvey |
| Regeneron Healthcare Solutions, INC. | $167.66 | 2025 | Libtayo, Lynozyfic |
| Beone Medicines USA, INC. | $153.80 | 2025 | Tevimbra, Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $151.63 | 2025 | Breyanzi, Opdivo |
| Amgen INC. | $129.05 | 2024 | Kyprolis |
| Abbvie INC. | $116.23 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.77 | 2024-2025 | Iclusig, Alunbrig, Ninlaro |
| Celgene Corporation | $69.26 | 2025 | Reblozyl |
| Eisai INC. | $65.34 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $62.11 | 2025 | Xtandi, Vyloy |
| Pfizer INC. | $54.48 | 2025 | |
| Merck Sharp & Dohme LLC | $54.31 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Tempus Ai, INC | $47.78 | 2025 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $44.33 | 2024 | Monoferric |
| Genzyme Corporation | $38.94 | 2024-2025 | |
| Geron Corporation | $38.12 | 2025 | Rytelo |
| Genentech USA, INC. | $33.57 | 2024 | Tecentriq, Tecentriq Hybreza, Phesgo |
| Bayer Healthcare Pharmaceuticals INC. | $33.53 | 2024-2025 | |
| Exelixis INC. | $24.83 | 2025 | Cabometyx |
| Sobi, INC | $24.77 | 2025 | |
| Kite Pharma, INC. | $24.36 | 2025 | Yescarta |
| Tersera Therapeutics LLC | $18.96 | 2025 | Zoladex |
| Secura Bio, INC. | $18.46 | 2024 | Copiktra |
| Lilly USA, LLC | $18.25 | 2024 | Retevmo |
| Puma Biotechnology, INC. | $14.74 | 2025 | |
| Recordati_rare_diseases_inc. | $13.81 | 2025 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousef Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.